Clinicopathological features of primary splenic histiocytic sarcoma: a case report and literature review / 中华血液学杂志

<p><b>OBJECTIVE</b>To study the clinicopathological features of primary splenic histiocytic sarcoma.</p><p><b>METHODS</b>Clinicopathological characterstics were analyzed in a case of primary splenic histiocytic sarcoma and related literatures were reviewed.</p><p><b>RESULTS</b>A 69-year old woman had unexplained debility and palpitation after exertion for a month. CT showed splenomegaly with multiple occupancy. The resected spleen measured 28 cm × 18 cm × 10 cm. Histopathological examination demonstrated that the neoplastic cells diffusely infiltrated splenic sinus. The neoplastic cells were characterized by well-defined cell contour, large pleomorphic nuclei, prominent nucleoli, and abundant eosinophilic cytoplasm. Tumor cells with cytoplasmic vacuoles and intense hemophagocytosis were observed. These cells strongly expressed histiocytic markers CD68 and CD163. Immunostaining for LCA, Vim was positive, but negative for CD1a, S-100, CD30, CK, CD20, CD3, CD21.</p><p><b>CONCLUSIONS</b>Immunohistochemistry plays a key role in the diagnosis of primary splenic histiocytic sarcoma.</p>

Expression of COX-2 and pregnancy associate plasma protein A in coronary arteries and their relationship with acute coronary syndrome: an autopsy study of 42 cases / 中华病理学杂志

<p><b>OBJECTIVE</b>To study the expression of COX-2 and pregnancy associate plasma protein A (PAPP-A) in coronary arteries and their relationship with acute coronary syndrome.</p><p><b>METHODS</b>Twenty-one autopsy cases with acute coronary syndrome encountered during the period from 2002 to 2007 were enrolled into the study. Another 21 autopsy cases without evidence of acute coronary syndrome were used as the controls. The right and left coronary arteries of each group were dissected, embedded and processed as paraffin sections. Immunohistochemical study for CD68 and alpha-actin was performed to highlight the presence of macrophages and smooth muscle cells, respectively. The expression of COX-2 and PAPP-A was evaluated.</p><p><b>RESULTS</b>In the acute coronary syndrome group, COX-2 was localized mainly in the cytoplasm of endothelial cells, macrophages and smooth muscle cells. COX-2 expression in the cytoplasm of smooth muscle cells (28.60%) was significantly higher than that in the control group (4.76%, chi(2) = 14.13, P< 0.05). There was a positive correlation on COX-2 and PAPP-A expression in smooth muscle cells of the media layer of coronary arteries in acute coronary syndrome group (r = 0.88, P < 0.05). The expression of PAPP-A in smooth muscle cells of the media layer in coronary arteries not associated with plaque formation, was higher than that when there were atherosclerotic plaques (chi(2) = 10.36, P < 0.05).</p><p><b>CONCLUSION</b>In coronary arteries, COX-2 and PAPP-A play certain roles in the pathogenesis of acute coronary syndrome.</p>

Preparation and evaluation in vivo and in vitro of glimepiride gel-matrix controlled-release patch / 药学学报

<p><b>AIM</b>To study the pharmaceutical characterization, the pharmacokinetics and relative bioavailability of glimepiride gel-matrix controlled-release patch in rats.</p><p><b>METHODS</b>An HPLC method was established for the determination of glimepiride in the permeation receptor and patch. The permeation rate and penetration mechanism of glimepiride-TDDS through rabbit skin in vitro was examined. The determination of drug content and the examination of weight difference and stability of the glimepiride-TDDS were carried out. Another HPLC method after pre-column derivatization was developed to determine the glimepiride serum concentration and then employed to study the pharmacokinetics and relative bioavailability of glimepiride after a single dose of oral or patch administration in rats.</p><p><b>RESULTS</b>The permeation tests through excised rabbit skin demonstrated that the optimized glimepiride controlled-release patch exhibited zero-order kinetic characteristics that satisfied the demands of original design. The determination of glimepiride content and the quality control of weight difference of the patch accorded with Pharmacopoeia of the People's Republic of China of 2000 edition and the pharmaceutical characterization showed good stability. The HPLC method for the determination of serum glimepiride was shown to be a sensitive and simple one. The pharmacokinetic results showed that TDDS could decrease the maximum serum concentration, prolong the peak time, extend the MRT by 5.5 times compared with oral administration and maintain the serum concentration of glimepiride at a higher level even after 120 h of administration. The relative bioavailability of glimepiride-TDDS was 20.3% versus oral administration.</p><p><b>CONCLUSION</b>The glimepiride-TDDS showed a slower, longer and smoother serum concentration-time profile, as compared with conventional oral administration in both absorption and elimination phase. As a result, it was evident that the patch exhibited good controlled-release properties.</p>